文献速递淋巴瘤造血干细胞移植与细胞治疗

C-CAR066:一种新型全人源抗CD20 CAR-T疗法用于抗CD19 CAR-T治疗失败后复发或难治性大B细胞淋巴瘤的I期临床研究

C-CAR066, a novel fully human anti-CD20 CAR-T therapy for relapsed or refractory large B-cell lymphoma after failure of anti-CD19 CAR-T therapy: A phase I clinical study.
PubMed 文献 · Am J Hematol · 2024-10-01

这项首次人体、单臂、I期研究在中国两个中心开展,评估C-CAR066(一种自体全人源抗CD20 CAR-T)用于抗CD19 CAR-T治疗失败后复发/难治性大B细胞淋巴瘤的安全性和疗效。14例患者接受单次静脉输注,目标剂量为2.0×10^6或3.0×10^6 CAR-T细胞/kg。截至2023年10月10日,总体缓解率为92.9%,完全缓解率为57.1%,中位随访27.7个月,中位无进展生存期为9.4个月(95% CI,2.0至NA),中位总生存期为34.8个月(95% CI,7.5至NA)。

要点

  • C-CAR066在抗CD19 CAR-T治疗失败后的复发/难治性大B细胞淋巴瘤中显示可管理的安全性和有前景的疗效。
  • 细胞因子释放综合征发生于12例(85.7%)患者,仅1例为4级;无患者发生免疫效应细胞相关神经毒性综合征。
  • 总体缓解率为92.9%,完全缓解率为57.1%;中位无进展生存期为9.4个月(95% CI,2.0至NA),中位总生存期为34.8个月(95% CI,7.5至NA)。

核心结论

  • C-CAR066在既往抗CD19 CAR-T治疗失败的患者中表现出可管理的安全性和有前景的疗效,为这类患者提供了一种有前景的治疗选择。

研究设计与样本

  • 首次人体、单臂、I期研究,在中国两个中心开展。
  • 纳入经组织学确诊为CD20阳性大B细胞淋巴瘤且必须接受过既往抗CD19 CAR-T治疗的患者。
  • 患者接受单次静脉输注C-CAR066,目标剂量为2.0×10^6或3.0×10^6 CAR-T细胞/kg。
  • 主要终点为不良事件(AEs)的发生率。
  • 截至2023年10月10日,共14例患者接受了C-CAR066治疗。

主要发现

  • 最常见的3级或以上不良事件为血液学毒性。
  • 细胞因子释放综合征发生于12例(85.7%)患者,仅1例为4级事件。
  • 无患者发生免疫效应细胞相关神经毒性综合征事件。
  • 总体缓解率为92.9%,完全缓解率为57.1%。
  • 中位随访27.7个月(范围,3.3-40.9),中位无进展生存期为9.4个月(95% CI,2.0至NA),中位总生存期为34.8个月(95% CI,7.5至NA)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Managing large B-cell lymphoma (LBCL) that is refractory to or relapsed after chimeric antigen receptor (CAR)-T therapy remains a significant challenge. Here we aimed to investigate the safety and efficacy of C-CAR066, an autologous fully human anti-CD20 specific CAR-T, for relapsed/refractory LBCL after failure of anti-CD19 CAR-T therapy. This first-in-human, single-arm, phase 1 study was conducted at two sites in China. Eligible patients had to be histologically confirmed with CD20-positive LBCL and must have received prior anti-CD19 CAR-T therapy. Patients received a single intravenous infusion of C-CAR066 at a target dose of 2.0 × 106 or 3.0 × 106 CAR-T cells/kg. The primary endpoint was the incidence of adverse events (AEs). As of October 10, 2023, 14 patients had received C-CAR066. The most common AEs of Grade 3 or higher were hematological toxicities. Cytokine release syndrome occurred in 12 (85.7%) patients, with only one was Grade 4 event. No patient experienced immune effector cell-associated neurotoxicity syndrome events. The overall response rate was 92.9% with a complete response rate of 57.1%. With a median follow-up of 27.7 months (range, 3.3-40.9), the median progression-free survival and overall survival were 9.4 months (95% CI, 2.0 to NA) and 34.8 months (95% CI, 7.5 to NA), respectively. C-CAR066 demonstrated a manageable safety profile and promising efficacy in patients in whom prior anti-CD19 CAR-T therapies had failed, providing a promising treatment option for those patients. This trial was registered with ClinicalTrials.gov, NCT04316624 and NCT04036019.

来源:Am J Hematol,查看原文。版权归原作者所有。

引用

  1. Li P, Liu W, Zhou L, et al. C-CAR066, a novel fully human anti-CD20 CAR-T therapy for relapsed or refractory large B-cell lymphoma after failure of anti-CD19 CAR-T therapy: A phase I clinical study. Am J Hematol. 2024. PMID: 39351902. doi:10.1002/ajh.27488

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。